Which antihypertensive drugs are the most nephroprotective and why?

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 16, 2010, Pages 2651-2663

  Cravedi, Paolo ^a   Ruggenenti, Piero ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Chronic kidney disease; Hypertension; Proteinuria

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; IRBESARTAN; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; MEDLINE; NEPHROANGIOSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; SODIUM RESTRICTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 78049402828     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.521742     Document Type: Review

References (84)

1. United States Renal Data System (USRDS), Annual report 2009 Available from: http://www.usrds.org/[Last accessed 5 August 2010.]
2. Sethi A, Arora R Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009;5:3-9
3. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-8
4. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989;13:180-93
5. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185-92
6. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008;40:1175-84
7. Norrelund H, Christensen KL, Samani NJ, et al. Early narrowed afferent arteriole is a contributor to the development of hypertension. Hypertension 1994;24:301-8
8. Kestenbaum B, Rudser KD, de Boer IH, et al. Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis. Ann Intern Med 2008;148:501-8
9. Freedman BI, Sedor JR Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008;19:2047-51
10. Ravera M, Re M, Deferrari L, et al. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 2006;17:S98-103
11. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33
12. Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet 2006;368:555-6
13. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51
14. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
15. Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006;29:595-600
16. Luft FC. Hypertensive nephrosclerosis-a cause of end-stage renal disease? Nephrol Dial Transplant 2000;15:1515-17
17. Fatica RA, Port FK, Young EW. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001;37:1184-90
18. Chapman A. Polycystic kidney disease: the cadence of kidney growth in ADPKD. Nat Rev Nephrol 2009;5:311-12
19. Stengel B, Billon S, Van Dijk PC, et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003;18:1824-33
20. Jafar TH, Stark PC, Schmid CH, et al. The effect of angiotensin- converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005;67:265-71
21. Chapman AB, Torres VE, Perrone RD, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010;5:102-9
22. Radin MJ, Wilke WL, Fettman MJ. Dose effect of captopril on renal hemodynamics and proteinuria in conscious, partially nephrectomized rats. Proc Soc Exp Biol Med 1989;190:294-300
23. Langham RG, Kelly DJ, Cox AJ, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45:1572-6
24. Deyneli O, Yavuz D, Velioglu A, et al. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst 2006;7:98-103
25. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
26. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45
27. The GISEN group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63
28. Ruggenenti P, Perna A, Mosconi L, et al.; Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998;53:1209-16
29. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31
30. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
31. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
32. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-7
33. Weir MR Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007;29:1803-24
34. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61
35. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007;18:1889-98
36. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828-31
37. Ruggenenti P, Cravedi P, Remuzzi G. Proteinuria: increased angiotensin-receptor blocking is not the first option. Nat Rev Nephrol 2009;5:367-68
38. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898-908
39. Kim HJ, Ryu JH, Han SW, et al. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy. Nephron Physiol 2004;97:p58-65
40. Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63:1094-103
41. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
42. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85
43. Ruggenenti P, Remuzzi G. Proteinuria: is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009;5:436-7
44. Allen TJ, Waldron MJ, Casley D, et al. Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes 1997;46:19-24
45. Fabris B, Jackson B, Johnston CI. Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension 1991;17:497-503
46. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008;19:999-1007
47. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486-92
48. Rossi GP. Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists? Curr Hypertens Rep 2006;8:262-8
49. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-8
50. Iwazu Y, Muto S, Fujisawa G, et al. Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis. Hypertension 2008;51:749-54
51. Lin S, Li D, Jia J, et al. Spironolactone ameliorates podocytic adhesive capacity via restoring integrin {alpha}3 expression in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 2010;11:149-57
52. Aldigier JC, Kanjanbuch T, Ma LJ, et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005;16:3306-14
53. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin- aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008;31:59-67
54. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009;20:2641-50
55. Cravedi P, Brusegan V, Ruggenenti P, et al. Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: does it really work? Pharmaceuticals 2010;3:1-9
56. Estacio RO. Renin-angiotensin-aldoster-one system blockade in diabetes: role of direct renin inhibitors. Postgrad Med 2009;121:33-44
57. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27
58. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008;93:557-63
59. Whaley-Connell A, Nistala R, Habibi J, et al. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2010;298:F655-61
60. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
61. Luno J, Garcia de Vinuesa S, Gomez-Campdera F, et al. Effects of antihypertensive therapy on progression of diabetic nephropathy. Kidney Int Suppl 1998;68:S112-19
62. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50
63. Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29:744-50
64. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004;65:1991-2002
65. Herlitz H, Harris K, Risler T, et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001;16:2158-65
66. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939-46
67. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
68. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
69. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
70. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study Ann Intern Med 1995;123:754-62
71. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52
72. Husten L. Calcium antagonist stopped in ABCD study. Appropriate blood pressure control in diabetes. Lancet 1998;351:P731
73. Appel L, Wright J, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918-29
74. Banach M, Mikhailidis DP, Kjeldsen SE, et al. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
75. Ruggenenti P, Perna A, Tonelli M, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol 2010 Jul 29 [Epub ahead ofprint]
76. Ruggenenti P, Perticucci E, Cravedi P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213-24
77. Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893-900
78. Hollenberg NK, Parving HH, Viberty G, et al. Albuminuria response to very high dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-6
79. Ruggenenti P, Mise N, Pisoni R, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003;107:586-92
80. Schjoedt KJ, Astrup AS, Persson F, et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia 2009;52:46-9
81. Rossing K, Christensen PK, Hansen BV, et al. Optimal dose of canderstartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomised cross-over study. Diabetes Care 2003;26:150-5
82. Houlihan CA, Allen TJ, Baxter AL, et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002;25:663-71
83. Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-5
84. Navis G, de Jong PE, Donker AJ et al. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 1987;31:815-9